HOME >> BIOLOGY >> NEWS
APS President-Elect Carey urges 6.7 percent increase for biomedical research

WASHINGTON -- (March 27, 2007) Hannah V. Carey, Ph.D., president-elect of The American Physiological Society (APS; www.the-aps.org) and a professor at the University of Wisconsin School of Veterinary Medicine, today urged Congress to increase funding for the National Institutes of Health (NIH), the nations largest funding source for biomedical research. A 6.7 percent increase in funding for the next fiscal year will help solve pressing health problems such as obesity, heart disease, diabetes and cancer, Carey told the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, and Education.

Carey expressed appreciation on behalf of the scientific community for doubling the NIH budget between 1998 and 2003. Since then, however, funding for the agency has not kept up with inflation. In fact, the NIH funds fewer than one out of five biomedical research grant applications, meaning that top-tier research is not being funded, Carey said. As a result, some of the best medical and scientific ideas are being left unexplored, and our most talented and creative scientists and our scientific leaders of the future are receiving a message of indifference.

Carey urged Congress to support a 6.7 percent increase for the NIH in each of the next three fiscal years. These increases would get the NIH back on track by restoring losses due to inflation in recent years. She also stressed the importance of NIH-funded training programs for the next generation of scientists and said NIH funds are essential to improving science education at all levels. The NIH also funds programs that provide important opportunities for minority students to become more deeply involved in scientific research.


'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
27-Mar-2007


Page: 1

Related biology news :

1. Contributing membership in the biomarkers consortium surges to 30 companies and nonprofits
2. AAAS urges US President to sign Embryonic Stem Cell Act
3. Virginia study urges early emphasis on science
4. NIH panel urges more informed approach to multivitamin/mineral use for chronic disease prevention
5. New journal article urges use of animal serum-free media for growing live cells
6. US Surgeon General urges Americans to know their family health history
7. To stem disease, keep cats indoors, stop feeding strays, scientist urges
8. AAAS CEO Alan I. Leshner urges US to continue collecting job data on women workers
9. Study urges caution in contaminant source tracking
10. The CF Foundation urges all states to include newborn screening for cystic fibrosis in test panels
11. New study warns limited carbon market puts 20 percent of tropical forest at risk

Post Your Comments:
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... dental biomaterial market will grow moderately through 2023 as ... and growing awareness of dental biomaterials all spur procedure ... such as China and ... bring dental procedures within reach for a larger proportion ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: